Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events

被引：108

作者：

Mukherjee, D ^{[1
]}

机构：

[1] Univ Michigan Hosp, Syst Hlth, Div Cardiol, Ann Arbor, MI 48103 USA

来源：

BIOCHEMICAL PHARMACOLOGY | 2002年 / 63卷 / 05期

关键词：

COX-2; inhibitors; prothrombotic effects; prostaglandins; rofecoxib; celecoxib; cardiovascular risk;

D O I：

10.1016/S0006-2952(02)00842-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Selective cyclooxygenase-2 (COX-2) inhibitors were developed as a response to the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents (NSAIDs). However, COX-2 inhibitors decrease vascular prostacyclin (PGI(2)) production and may disrupt the homeostatic mechanisms that limit the effects of platelet activation. Basic and clinical data raise concerns about a potential prothrombotic effect of this class of drugs. The widespread popularity of these agents mandates their prospective evaluation in patients with cardiovascular diseases or who are at risk for cardiovascular events. (C) 2002 Elsevier Science Inc. All rights reserved.

引用

页码：817 / 821

页数：5

共 28 条

[1]

Belton O, 2000, CIRCULATION, V102, P840

[2] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[3] EVALUATION OF FLURBIPROFEN FOR PREVENTION OF REINFARCTION AND REOCCLUSION AFTER SUCCESSFUL THROMBOLYSIS OR ANGIOPLASTY IN ACUTE MYOCARDIAL-INFARCTION [J].

BROCHIER, ML .

EUROPEAN HEART JOURNAL, 1993, 14 (07) :951-957

[4] Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis [J].

Cataldo, G ;

Heiman, F ;

Lavezzari, M ;

Marubini, E .

CORONARY ARTERY DISEASE, 1998, 9 (04) :217-222

[5]

Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735

[6]

Clarke R, 1999, AM J EPIDEMIOL, V150, P341

[7] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].

COLLINS, R ;

PETO, R ;

MACMAHON, S ;

HEBERT, P ;

FIEBACH, NH ;

EBERLEIN, KA ;

GODWIN, J ;

QIZILBASH, N ;

TAYLOR, JO ;

HENNEKENS, CH .

LANCET, 1990, 335 (8693) :827-838

[8] Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo [J].

Dowd, NP ;

Scully, M ;

Adderley, SR ;

Cunningham, AJ ;

Fitzgerald, DJ .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (04) :585-590

[9]

*FDA, 2001, POSTM SAF REV

[10]

*FDA, 2001, CARD SAF REV REC

← 1 2 3 →